LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lenz Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.476 Good afternoon, ladies and gentlemen, and welcome to the Lens Therapeutics first quarter 00:00:04.476 -- 00:00:10.143 2026 financial results conference call. At this time, all participants 00:00:10.143 -- 00:00:13.908 are in a listen-only mode. Following 00:00:13.908 -- 00:00:19.795 prepared remarks from management, we will conduct a question and answer session, and 00:00:19.795 -- 00:00:25.002 instructions will follow at that time. As a reminder, this call is being 00:00:25.002 -- 00:00:31.006 recorded. At this time, I would like to turn the call over to Dan Chevalard, 00:00:31.006 -- 00:00:34.889 Chief Financial Officer, please go ahead. 00:00:35.854 -- 00:00:39.521 Thank you. Good afternoon, and thank you for joining us today. 00:00:39.521 -- 00:00:43.788 My name is Dan Chevalard, Chief Financial Officer of Lens Therapeutics. 00:00:43.788 -- 00:00:48.617 We are joined today by Abe Skimel-Pennick, our President and Chief Executive Officer, 00:00:48.617 -- 00:00:52.003 Sean Olson, our Chief Commercial Officer, and Dr. 00:00:52.003 -- 00:00:55.583 Mark Odrich, our Chief Medical Officer. 00:00:55.583 -- 00:00:59.326 Before we begin, I would like to remind you that this call will contain forward-looking 00:00:59.326 -- 00:01:04.491 statements regarding LENZ's future expectations, plans, prospects, 00:01:04.491 -- 00:01:09.756 corporate strategy, regulatory and commercial plans and expectations, cash runway 00:01:09.756 -- 00:01:11.978 projections and performance. 00:01:11.978 -- 00:01:17.223 Actual results may differ materially from those indicated by these forward-looking statements 00:01:17.223 -- 00:01:22.448 as a result of various important factors and risks, including those discussed 00:01:22.448 -- 00:01:27.598 in our filings w...